Open-angle Glaucoma, Ocular Hypertension
Conditions
Brief summary
AEs, visual field, visual acuity, macroscopic conjunctival hyperemia, slit-lamp biomicroscopic assessments, dilated ophthalmoscopic assessments (including optic disc assessment), contact ultrasound pachymetry, gonioscopy (implant assessment), and specular microscopy., Key endpoint: time from last Bimatoprost SR treatment in the lead-in study to first rescue treatment or first Bimatoprost SR PRN retreatment, Additional endpoints: time from SLT treatment in the lead-in study to first rescue treatment in the SLT-treated eye (Phase 3 study comparator) for patients from Study 192024-093 or -095
Interventions
DRUGBimatoprost SR
Sponsors
AbbVie Deutschland GmbH & Co. KG
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AEs, visual field, visual acuity, macroscopic conjunctival hyperemia, slit-lamp biomicroscopic assessments, dilated ophthalmoscopic assessments (including optic disc assessment), contact ultrasound pachymetry, gonioscopy (implant assessment), and specular microscopy., Key endpoint: time from last Bimatoprost SR treatment in the lead-in study to first rescue treatment or first Bimatoprost SR PRN retreatment, Additional endpoints: time from SLT treatment in the lead-in study to first rescue treatment in the SLT-treated eye (Phase 3 study comparator) for patients from Study 192024-093 or -095 | — |
Countries
France, Germany, Poland, Spain
Outcome results
None listed